Foghorn Therapeutics Inc FHTX

NAS: FHTX | ISIN: US3441741077   17/05/2024
5,510 USD (-5,16%)
(-5,16%)   17/05/2024

1 november 2023 · Flagship Pioneering Launches Pioneering Intelligence · Persbericht

11 september 2023 · Flagship Pioneering Announces Appointment of Amanda Kay as Chief Business Development Officer · Persbericht

29 augustus 2023 · Invaio achieves first registration for citrus greening solution featuring Trecise™ technology · Persbericht

16 mei 2023 · Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry · Persbericht

28 februari 2022 · Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs · Persbericht

15 februari 2022 · Invaio Sciences Strengthens Its Board Of Directors With The Appointment Of Hugh Grant · Persbericht

13 december 2021 · Lilly and Foghorn Announce Strategic Collaboration for Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control® Platform · Persbericht

13 oktober 2021 · Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change · Persbericht

25 mei 2021 · Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture · Persbericht

19 mei 2021 · Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening · Persbericht

30 maart 2021 · Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer · Persbericht

18 maart 2021 · Foghorn Therapeutics Provides Corporate Update · Persbericht

11 maart 2021 · UPDATE: Foghorn Therapeutics to Present Poster and Chair a Panel at the AACR Annual Meeting 2021 · Persbericht

11 maart 2021 · Foghorn Therapeutics to Present Poster and Chair a Panel and at the AACR Annual Meeting 2021 · Persbericht

25 februari 2021 · Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target · Persbericht

Mijn selecties